Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000697
Filing Date
2025-11-14
Accepted
2025-11-14 15:45:16
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10334
2 ex991.htm EX-99.1 AGREEMENT 3916
  Complete submission text file 0000935836-25-000697.txt   15878
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Subject) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90187 | Film No.: 251485269
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 357 TEHAMA STREET #3 SAN FRANCISCO CA 94103
Business Address 357 TEHAMA STREET #3 SAN FRANCISCO CA 94103 415-448-6534
EcoR1 Capital, LLC (Filed by) CIK: 0001587114 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A